Drugs / Ponezumab
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01125631 | May 2010 → Aug 2011 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01005862 | Mar 2010 → Sep 2012 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00733642 | Aug 2008 → Jul 2009 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00607308 | Feb 2008 → Oct 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00455000 | Mar 2007 → Sep 2009 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01821118 | Jun 2013 → Sep 2015 | cerebral amyloid angiopathy | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00945672 | Aug 2009 → Jun 2011 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00722046 | Dec 2008 → Aug 2011 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ponezumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01821118 ↗ |
| Known as | PF-04360365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01125631 ↗ |
| Known as | RN-1219 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743058 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody” NCT00455000 ↗ |
| Route | Intravenous | “a single IV dose of PF-04360365” NCT00455000 ↗ |
| Target | APP | “Amyloid-beta A4 protein binding agent” CHEMBL1743058 ↗ |